Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: Simple or complex pharmacokinetic methods?

Clinical Pharmacokinetics

Volumn 40, Issue 11, 2001, Pages 803-814

  Tod, M M ^a,b   Padoin, C ^a   Petitjean, O ^a  

^a AVICENNE HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE;

ACCURACY; ARTIFICIAL NEURAL NETWORK; BAYES THEOREM; BLOOD SAMPLING; COMPARTMENT MODEL; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG INFUSION; DRUG MONITORING; POPULATION MODEL; PRIORITY JOURNAL; REGRESSION ANALYSIS; REVIEW;

EID: 0035177895     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200140110-00002     Document Type: Review

References (49)

1. Gentamicin pharmacokinetics in 1640 patients: Method for control of serum concentrations
2. Wide interpatient variations in gentamicin dose requirements for geriatric patients
3. Aminoglycoside pharmacokinetic monitoring: An integral part of patient care?
4. The pharmacodynamics of aminoglycosides
5. A critical reevaluation of the 'therapeutic range' of aminoglycosides
6. A controlled trial of the cost benefit of computerized Bayesian aminoglycoside administration
7. Experience with once-daily aminoglycoside program administered to 2184 adult patients
8. Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity
9. Once-daily dosing of aminoglycosides: A consensus document
10. Some international approaches to aminoglycoside monitoring in the extended dosing interval era
11. Cost considerations in therapeutic drug monitoring of aminoglycosides
12. Prospective evaluation of the effects of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity
13. Once daily amino-glycoside therapy: Is it less toxic than multiple daily doses and how should it be monitored?
14. Clinical pharmacokinetics and pharmacokinetics of isepamicin
15. Aminoglycoside pharmacokinetics: Volume of distribution in specific adult patient subgroups
16. Variability in aminoglycoside pharmacokinetics in critically ill surgical patients
17. Aminoglycoside volume of distribution and illness severity in critically ill septic patients
18. The pharmacokinetics of prophylactic antibiotics in trauma
19. Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy
20. A suggested approach to once-daily aminoglycoside dosing
21. Adaptive resistance of Pseudomonas aeruginosa induced by aminoglycosides and killing kinetics in a rabbit endocarditis model
22. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome
23. Experience of once-daily aminoglycoside dosing using a target area under the concentration-time curve
24. Ototoxicity induced by once-daily gentamicin
25. Isepamicin in intensive care unit patients with nosocomial pneumonia: Population pharmacokinetic-pharmacodynamic study
26. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer
27. Increased aminoglycoside dosage requirements in hematologic malignancy
28. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: Gentamicin in burn patients
29. Computers in pharmacokinetics: Choosing software for clinical decision making
30. Individualising gentamicin dosage regimens: A comparative review of selected models, data fitting methods and monitoring strategies
31. Aminoglycoside forecasting in neutropenic patients with cancen
32. Evaluation of Bayesian forecasting for individualized gentamicin dosage in infants weighing 1000 g or less
33. Bayesian forecasting of aminoglycoside dosing requirements in obese patients: Influence of subpopulation versus general population pharmacokinetic parameters as the internal estimates
34. Implementation and evaluation of control strategies for individualizing dosage regimens, with application to aminoglycoside antibiotics
35. Achieving target goals most precisely using non parametric compartmental models and multiple model design of dosage regimens
36. Implementation and evaluation of a stochastic control strategy for individualizing teicoplanin dosage regimen
37. The back propagation neural network -a Bayesian classifier: Introduction and applicability to pharmacokinetics
38. Neural network predicted peak and trough gentamicin concentrations
39. Nonpharmacokinetic clinical factors affecting aminoglycoside therapeutic precision: A simulation study
40. Estimates of the population pharmacokinetic parameters and performance of Bayesian feedback: A sensitivity analysis
41. Predictive performance of the Bayesian analysis: Effect of blood sampling time, population parameters and pharmacostatistical model
42. Nonparametric meta-analysis of published data on kidney-function dependence of pharmacokinetic parameters for the aminoglycoside netilmicin
43. Unpredictability of clinical evaluation of renal function in cirrhosis
44. The evaluation of creatinine clearance in spinal cord injury patients
45. Bayesian analysis of realistically complex models
46. Aminoglycosides: Antimicrobial therapy - II
47. Aminoglycoside penetration, inactivation and efficacy in cystic fibrosis sputum
48. Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis